NYSE · MTD
Healthcare · Medical - Diagnostics & Research
$1,330.40
Up+$44.65 (+3.47%)
Updated Sep 16, 2026, 12:03 PM
SID Score
4.7/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
MTD closed at $1,330.40 after 20 trading sessions, down 4.95% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $1,293.46 | $1,335.84 | $1,284.7254 | $1,330.40 | 211.75K |
| Sep 14, 2026 | $1,302.88 | $1,306.14 | $1,274.51 | $1,285.75 | 206K |
| Sep 11, 2026 | $1,294.03 | $1,302.845 | $1,286.66 | $1,293.52 | 96.7K |
| Sep 10, 2026 | $1,275.79 | $1,296.6461 | $1,266.55 | $1,280.58 | 185.9K |
| Sep 9, 2026 | $1,303.57 | $1,316.39 | $1,288.84 | $1,290.36 | 193.68K |
| Sep 8, 2026 | $1,331.81 | $1,347.85 | $1,322.92 | $1,325.52 | 151.12K |
| Sep 4, 2026 | $1,341.57 | $1,358.78 | $1,339.09 | $1,345.26 | 103.03K |
| Sep 3, 2026 | $1,376.16 | $1,387.32 | $1,334.73 | $1,356.23 | 168.38K |
| Sep 2, 2026 | $1,361.36 | $1,398.13 | $1,357.19 | $1,367.74 | 178.97K |
| Sep 1, 2026 | $1,410.75 | $1,415.00 | $1,370.33 | $1,375.96 | 168.55K |
| Aug 31, 2026 | $1,384.20 | $1,407.11 | $1,376.235 | $1,405.14 | 221.17K |
| Aug 28, 2026 | $1,401.09 | $1,406.925 | $1,391.6171 | $1,398.58 | 202.02K |
| Aug 27, 2026 | $1,406.36 | $1,440.22 | $1,400.61 | $1,407.43 | 146.07K |
| Aug 26, 2026 | $1,392.11 | $1,413.406 | $1,390.81 | $1,398.46 | 97.13K |
| Aug 25, 2026 | $1,413.57 | $1,421.775 | $1,395.985 | $1,402.25 | 116.92K |
| Aug 24, 2026 | $1,393.48 | $1,419.10 | $1,385.675 | $1,398.89 | 164.4K |
| Aug 21, 2026 | $1,385.99 | $1,404.515 | $1,377.0994 | $1,395.25 | 365.59K |
| Aug 20, 2026 | $1,408.57 | $1,447.65 | $1,387.67 | $1,393.23 | 444.6K |
| Aug 19, 2026 | $1,423.17 | $1,456.77 | $1,419.41 | $1,425.09 | 121.75K |
| Aug 18, 2026 | $1,427.61 | $1,427.61 | $1,396.12 | $1,399.67 | 140.59K |
The latest Smart Investors Daily articles mentioning MTD.
MTD research
Company profile and research snapshot.
Mettler-Toledo supplies weighing and precision instruments to customers in the life sciences (around 55% of sales), industrial (around 40%), and food retail (around 5%) industries. Its products include laboratory and retail scales, pipettes, pH meters, thermal analysis equipment, titrators, metal detectors, and X-ray analyzers. Mettler leads the market for weighing instrumentation and controls more than 50% of the market for lab balances. The business is geographically diversified, with the Americas accounting for about 37% of sales, Europe about 28%, China about 16% and the rest of the world about 19%.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 2, 2026 | Rothschild & Co | Sell | — |
| Sep 1, 2026 | RBC Capital | Sector Perform | — |
| Aug 4, 2026 | Morgan Stanley | Equal-Weight | — |
| Aug 3, 2026 | Evercore ISI Group | Outperform | — |
| Aug 3, 2026 | Wells Fargo | Equal-Weight | — |
No generated briefing is available yet.
Yahoo · Sep 10, 2026
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Mettler-Toledo (NYSE:MTD) and its peers.
ChartMill · Sep 10, 2026
Mettler-Toledo (MTD) passes the Caviar Cruise quality screen with 66.67% ROIC, strong cash conversion, low debt/FCF, and durable growth, but rich valuation.
Fintel · Sep 3, 2026
Yahoo · Sep 2, 2026
Investing.com -- Mettler-Toledo faces a growing mismatch between its premium valuation and a more modest growth outlook as competition intensifies across its weighing and laboratory businesses, brokerage Redburn said on Wednesday, initiating coverage of the precision-instrument maker with a Sell rating.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MTD.
